Short-term effect of lodine-131-1abeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer and the observation of radionuclide imaging
- Author:
- No author available
- Journal Title:
- CHINA CLINICAL PRACTICAL MEDICINE
- Issue:
- 12
- DOI:
- No doi available
- Key Word:
- 单克隆抗体;131I-chTNT;肺癌;放射免疫治疗;Monoclonal antibody;131I-chTNT;Lung cancer;Radioimmunotherapy
Abstract： Objective To assess the therapeutic efficacy of Iodine-131-1abeled chimeric tumor necrosis treatment radioimmunotherapy(131 I-chTNT) in patients with advanced lung cancer. Methods 15 patients con-firmed diagnosis of advanced lung cancer were treated with intravenous injections of 131I-chTNT, and radionu-clide imaging was performed at 1,3,5,7,9,15 day after therapy ,the objective response rate(ORR) was used to assess the therapeutic efficacy. Results The results showed an ORR of 40% (complete response, 1 case; partial response,5 cases; no change,7 cases; and progressive disease,2 cases); radionuclide imaging study demon-strated that 131I-chTNT had a long and stable retention in lung tumor. The most obvious adverse side effect was mild and reversible bone marrow suppression. Conclusion The short-term effect of 131I-chTNT in patients with advanced lung cancer is good, radionuclide imaging after therapy can objectively show localization of the radioac-tivity in tumors
- [1]A L, Epstein,F M, Chen,C R, Taylor.A novel method for the detection of necrotic lesions in human cancers.[J].1988,48(20).
- [2]J L, Hornick,J, Sharifi,L A, Khawli,etc.A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors.[J].1998,13(4).
- [3]Goldenberg DM.Targeted therapy of cancer with radiolabeled antibodies.[J].2002,43(5).
- [4]Yu L,Chen W,Jiang C,etc.131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer.[J].2006,21(1).
- [5]C, Manegold.Chemotherapy for advanced non-small cell lung cancer: standards.[J].2001,34 Suppl 2.
- [6]Alauddin MM,Khawli LA,Hu P,etc.Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.[J].2003,18(6).
- [7]Alauddin MM,Khawli LA,Mizokami MM,etc.Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.[J].2000,41(2).
- [8]Robert O, Dillman.Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.[J].2002,20(16).